Quick Answer
Vera Therapeutics, Inc. reported Total Assets of $734.73 million for the year ending 2025.
- Vera Therapeutics, Inc. showed an increase of +12.1% in Total Assets from 2024 to 2025.
- This data is from Vera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $51.83 million | Q2 2021: $97.65 million | Q3 2021: $91.17 million | Q1 2022: $164.97 million | Q2 2022: $148.78 million | Q3 2022: $131.37 million | Q1 2023: $209.60 million | Q2 2023: $195.18 million | Q3 2023: $175.62 million | Q1 2024: $419.36 million | Q2 2024: $397.29 million | Q3 2024: $368.56 million | Q1 2025: $610.17 million | Q2 2025: $578.53 million | Q3 2025: $517.50 million.
- Over the full 6 years of available data (2020 to 2025), Vera Therapeutics, Inc.'s Total Assets has grown by 1,246.8%.
- Historical annual values: Fiscal year 2025: $734.73 million | Fiscal year 2024: $655.68 million | Fiscal year 2023: $175.55 million | Fiscal year 2022: $131.44 million | Fiscal year 2021: $83.75 million | Fiscal year 2020: $54.55 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: